Filer Snapshot

ORAMED PHARMACEUTICALS INC.

CIK 0001176309. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

147

Latest filing

14 Aug 2026

Industry

Pharmaceutical Preparations

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13D/G stake for NNDM. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13D/G history Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

NNDM

20 Jul 2026 · 3.3% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Schedule 13D/G

SCHEDULE 13G/A filed on 14 Aug 2026 for CIK 0001176309.

View source filing
Listed symbols
ORMP on Nasdaq
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

Forms 3/4/5 positions$800.2K

Reporting-owner positions with enough filing detail to estimate value.

Forms 3/4/5 position value

3/4/5
$800.2K

Estimated from parsed Forms 3/4/5 when filings include enough share and price data.

Source: Forms 3/4/5Confidence: Estimated when price data is available

Largest linked holdings

Largest issuer positions linked to this CIK across parsed 13F, 13D/G, and Forms 3/4/5 records.

LFWD

Largest active 13D stakes

Active large-stake positions disclosed in parsed Schedule 13D filings.

DRTS NNDM LFWD

Largest active 13G stakes

Passive or institutional large-stake positions disclosed in parsed Schedule 13G filings.

SCLX
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 2 identity fields
SEC industry group
Pharmaceutical Preparations (Office of Life Sciences)
Business address
1185 Avenue Of The Americas, 3 Rd Floor, New York, NY, 10036
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 3 profile fields available
Incorporated in
DE
Fiscal year end
31 December
Former names on EDGAR
Integrated Security Technologies, Inc. (to 10 Apr 2006), IGUANA VENTURES LTD (to 10 Jun 2004)

Filer intelligence

What SEC filings say about ORAMED PHARMACEUTICALS INC.

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

Quick read

  • 5 recent 13D/G stake rows found; top row is NNDM at 3.3% ownership.
  • Forms 3/4/5 show insider context for LFWD worth $800.2K.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

Open
13D/G stakes 5 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 1 rows

Officer, director, and 10% owner holdings or transactions.

Open

13D/G large-stake context

NNDM

20 Jul 2026 · Ordinary Shares, par value NIS 5.00 per share

3.3%
Issuer page 13D/G history

LFWD

25 Mar 2026 · Ordinary Shares, no par value

50%
Issuer page 13D/G history

SCLX

31 Dec 2025 · Common Stock, par value $0.0001 per share

4.9%
Issuer page 13D/G history

DRTS

24 Apr 2025 · Ordinary shares, no par value

20%
Issuer page 13D/G history

Forms 3/4/5 insider context

LFWD

25 Mar 2026 · 10% owner

$800.2K
Issuer page Owner page

Latest update

What changed recently for ORAMED PHARMACEUTICALS INC.

New fact period available

Latest financial period: Q2 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

10 Aug 2026

Page type

Company facts

Latest period

Q2 2026

SEC-backed company facts were refreshed from filings filed on 10 Aug 2026.

Open company facts Browse recent public updates

Benchmark Context

Benchmark context for this company

ORAMED PHARMACEUTICALS INC. has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest financial period: Q2 2026. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 10 Aug 2026.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0001176309 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
147
First seen
08 Jul 2021
Latest filing
14 Aug 2026
Entity
Company

Observed form types

10-K 10-K/A 10-Q 3 4 4/A 5 SCHEDULE 13D SCHEDULE 13D/A SCHEDULE 13G +1 more

CIK-linked evidence first

ORAMED PHARMACEUTICALS INC. SEC filings ORAMED PHARMACEUTICALS INC. 13D/G history ORAMED PHARMACEUTICALS INC. owner filings ORAMED PHARMACEUTICALS INC. insider transactions ORAMED PHARMACEUTICALS INC. company facts Open SEC filing index

Industry context: Pharmaceutical Preparations.

Latest Filings

Showing the latest 12 of 147 SEC filings for ORAMED PHARMACEUTICALS INC..

Open full filing history
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
22 Jul 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
02 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
02 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
17 Jun 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q

10-Q filing

Filing date
19 May 2026
Reporting date
31 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D

SCHEDULE 13D filing

Filing date
14 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
31 Mar 2026
Reporting date
30 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
31 Mar 2026
Reporting date
30 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
10-K

10-K filing

Filing date
26 Mar 2026
Reporting date
31 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
18 Mar 2026
Reporting date
17 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
18 Mar 2026
Reporting date
17 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .